CN Patent

CN116507320A — 与延长释放帕潘立酮可注射制剂相关的给药方案

Assigned to Janssen Pharmaceutica NV · Expires 2023-07-28 · 3y expired

What this patent protects

本发明提供了用长效可注射棕榈酸帕潘立酮制剂治疗患者的方法。

USPTO Abstract

本发明提供了用长效可注射棕榈酸帕潘立酮制剂治疗患者的方法。

Drugs covered by this patent

Invega Sustenna (PALIPERIDONE PALMITATE) · Johnson & Johnson

Patent Metadata

Patent number: CN116507320A
Jurisdiction: CN
Classification: —
Expires: 2023-07-28
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Pharmaceutica NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.